| http://www.w3.org/ns/prov#value | - To further evaluate safety and toxicity in this patient population. [ Time Frame: every 2 weeks ] [ Designated as safety issue: Yes ]Safety assessments will consist of monitoring and recording all adverse events, including serious adverse events, the regular monitoring of hematology (including glycosylated hemoglobin and coagulation parameters), blood chemistry (including fasting glucose, thyroid
|
